ZyVersa Therapeutics announces a new SAB to support advancement of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications. Based on its mechanism of action, IC 100, in combination with incretin therapy, is anticipated to augment weight loss, but more importantly, to attenuate the chronic systemic inflammation leading to metabolic complications and other inflammatory comorbidities of obesity. Members of ZyVersa’s Obesity, Metabolic and Inflammatory Diseases SAB are listed. Caroline M. Apovian, MD, FACP, FTOS, DABOM Co-Director, Center for Weight Management and Wellness, Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women’s Hospital. Harold Bays, MD, MFOMA, FTOS, FACC, FACE, FNLA, FASPC Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center. Helen Bramlett, PhD Professor, Department of Neurological Surgery, University of Miami Miller School of Medicine. Marc-Andre Cornier, MD Professor of Medicine, Medical University of South Carolina. W. Dalton Dietrich, III, PhD Kinetic Concepts Distinguished Chair in Neurosurgery, and Scientific Director. Robert W. Keane, PhD Professor, Physiology and Biophysics, Neurological Surgery and Microbiology, and Immunology, University of Miami Miller School of Medicine. Samuel Klein, MD William H. Danforth Professor of Medicine, Washington University School of Medicine. Suneil Koliwad, MD, PhD Chief, Division of Endocrinology and Metabolism, UCSF Health.